(Q42980145)

12 November 2017

title

Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy (English)

1 reference

12 November 2017

Hepatitis c virus-specific cytolytic t cell responses after antiviral therapy (English)

1 reference

https://api.crossref.org/works/10.1016/S1521-6616(03)00142-6

11 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1521-6616(03)00142-6

11 March 2024

8

M Juliana McElrath

1 reference

12 November 2017

1

Chihiro Morishima

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14499244

11 March 2024

author name string

Luwy Musey

2

1 reference

12 November 2017

Marnie Elizaga

3

1 reference

12 November 2017

Kersten Gaba

4

1 reference

12 November 2017

Megan Allison

5

1 reference

12 November 2017

Robert L. Carithers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14499244

11 March 2024

David R. Gretch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14499244

11 March 2024

M. Juliana McElrath

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14499244

11 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14499244

11 March 2024

publication date

1 September 2003

1 reference

full work available at URL

12 November 2017

https://api.elsevier.com/content/article/PII:S1521661603001426?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1521-6616(03)00142-6

https://api.elsevier.com/content/article/PII:S1521661603001426?httpAccept=text/plain

11 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1521-6616(03)00142-6

11 March 2024

1 reference

12 November 2017

volume

108

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

211-220

1 reference

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Analysis of successful immune responses in persons infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Analysis of a successful immune response against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Quantification of serum hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Comprehensive Analysis of CD8+-T-Cell Responses against Hepatitis C Virus Reveals Multiple Unpredicted Specificities

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Detection of Diverse Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes in Peripheral Blood of Infected Persons by Screening for Responses to All Translated Proteins of HCV

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Inhibition of immune functions by antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2803%2900142-6

7 January 2021

Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus

40

1 reference

https://api.crossref.org/works/10.1016/S1521-6616(03)00142-6

11 March 2024

Identifiers

1 reference

12 November 2017

1 reference